FDA Policy Power Challenged In House Questions On Untitled Letters
This article was originally published in The Gray Sheet
House lawmakers want to know if FDA is aware of consequences of publishing letters during stock trading hours.
You may also be interested in...
In Case You Missed It: Top 10 "Gray Sheet" Stories In June
"The Gray Sheet" offerings that captured the most Web traffic last month centered on device recall trends, combination products, exclusive interviews with two FDA officials and our new Device Week podcast.
FDA, 23andMe Open Up Market Pathway For DTC Genetics
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.